China-based contract development and manufacturing organization (CDMO) Apeloa Pharmaceutical Co., Ltd (SHE: 000739) has announced a strategic partnership agreement with Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266). The collaboration is set to focus on long-term CDMO programs, with specific financial details not disclosed in the announcement.
Collaboration on CDMO Programs
The partnership between Apeloa and Zelgen aims to leverage their combined expertise in the pharmaceutical industry. Apeloa, with its advanced manufacturing facilities, research and development capabilities, quality management, and environmental, health, and safety (EHS) control systems, is well-positioned to support the development and manufacturing of raw materials and intermediates for Zelgen’s pharmaceutical programs.
Enhancing Pharmaceutical Development and Manufacturing
This collaboration is expected to enhance the development and manufacturing processes for both companies, potentially leading to more efficient and effective pharmaceutical solutions. The long-term nature of the agreement signifies a commitment to ongoing collaboration and the development of innovative CDMO programs in the Chinese pharmaceutical market.-Fineline Info & Tech
